Collaborations

The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need.

CureVac collaborates with CRISPR Therapeutics, a genome editing company focused on creating transformative gene-based medicines for serious diseases, for developing CRISPR-based therapeutics in select disease areas. Under the terms of the agreement, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.

In July 2024, CureVac has out-licensed to GSK its respiratory infectious disease programs, including seasonal and avian influenza, COVID-19, as well as a flu/COVID-19 combination.

CureVac partnered with myNEO Therapeutics in its off-the-shelf cancer vaccines program to identify novel tumor-associated antigens, applying myNEO Therapeutics' advanced AI-powered technology platform.

CureVac cooperates with Acuitas Therapeutics Ltd, a company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. This collaboration will allow CureVac to access the full patent portfolio and know-how of Acuitas and its lipid technology. The objective of the collaboration is the development of LNP-formulated mRNA product candidates.